Last updated: July 24, 2026
PREVPAC (lansoprazole/clarithromycin/amoxicillin) Clinical Trials Update, Market Analysis, and Exclusivity & Generic Entry Outlook
Executive summary: PREVPAC is an FDA-approved, fixed-dose 14-day combination regimen of lansoprazole + clarithromycin + amoxicillin for H. pylori eradication. Clinical-trial activity for PREVPAC is low in recent years because the product is an older, legacy regimen built from components with largely established development histories. Near-term competitive and commercial dynamics are driven by (1) generic availability of the individual components, (2) regulatory and labeling stability of the combination regimen, (3) pricing pressure from generics and payer controls, and (4) the decline in helicobacter testing intensity in some settings, partially offset by guideline-driven eradication workflows. Patent and exclusivity risk centers on whether any combination-use or formulation patents remain enforceable for the fixed regimen, balanced against long-established availability of generic lansoprazole, clarithromycin, and amoxicillin. Market projection is therefore best modeled as a mature, commoditized branded legacy product with limited growth and continued erosion from generics.
What clinical trials exist for PREVPAC (lansoprazole clarithromycin amoxicillin) and what are the latest updates?
Featured snippet: No meaningful, recent PREVPAC-specific late-stage trials are visible in public registries compared with newer eradication regimens, reflecting that the regimen is an established fixed-dose combination.
Are there current or recently completed PREVPAC trials registered on ClinicalTrials.gov?
Most H. pylori eradication clinical development in the last decade has shifted to:
- Newer antibiotic combinations and proprietary delivery strategies
- Reformulations aimed at overcoming macrolide resistance
- Alternative regimens aligned to updated guideline trends
PREVPAC itself is generally treated as a legacy regimen, and recent trial registration and public results often focus on:
- Component-level pharmacology
- Comparative eradication outcomes using alternative PPI/antibiotic structures
- Real-world adherence and resistance stratification rather than PREVPAC fixed-dose iteration
What outcomes matter for PREVPAC in H. pylori eradication studies?
For decision-making around any remaining clinical differentiation, the metrics that typically govern regimen adoption are:
- Intention-to-treat (ITT) eradication rates
- Per-protocol eradication rates
- Adverse event rates (especially GI intolerance)
- Adherence and completion rates across a 14-day course
- Resistance patterns, particularly macrolide resistance impacts on clarithromycin-containing regimens
How does PREVPAC performance depend on clarithromycin resistance?
The clinical adoption of clarithromycin-based triples has varied materially with geographic clarithromycin susceptibility. In higher resistance settings, eradication outcomes decline, which affects payer preference and guideline positioning for regimens similar to PREVPAC.
How big is the PREVPAC market today and what is the revenue exposure to generic erosion?
Featured snippet: PREVPAC operates in a mature H. pylori eradication market where branded exposure is structurally constrained by generic component substitution and payer-driven switching.
Market structure for H. pylori eradication regimens
The commercial market is segmented by:
- Regimen class (PPI-based triple therapies, bismuth quadruples, and newer alternatives)
- Antibiotic resistance environment
- Provider preference and test-and-treat adoption
- Managed care contracting and dispensing controls
PREVPAC pricing and volumes typically face pressure from:
- Generic lansoprazole
- Generic clarithromycin
- Generic amoxicillin
- Off-instruction substitution where prescribers are not locked to fixed-dose products
What drives payer decisions for PREVPAC?
Key levers include:
- Average wholesale price and contracted net price for branded fixed-dose combinations
- Copay design and prior authorization norms
- Therapeutic interchange rules at the plan and PBM levels
- Formulary placement relative to newer regimens
Where is demand most exposed?
Demand tends to be most exposed where:
- Clarithromycin-based regimens are de-emphasized due to resistance
- Prescribers shift to alternatives (bismuth quadruple strategies or susceptibility-guided approaches)
- Testing protocols reduce empirical macrolide-containing prescribing
When does PREVPAC lose exclusivity and what does that mean for generic launch timing?
Featured snippet: Specific exclusivity and expiration timelines require a current, source-backed review of FDA Orange Book listings and patent term calculations. A rigorous exclusivity calendar cannot be produced here without the underlying Orange Book and patent event data.
What exclusivity categories are relevant for fixed-dose combinations like PREVPAC?
For branded combination products, the exclusivity stack usually includes:
- New Chemical Entity (NCE) exclusivity (often irrelevant for older PPIs and generics)
- New Combination exclusivity if applicable
- Patent term protections covering formulation, method-of-use, or combination-specific dosing
- Orphan or other special exclusivity are not typical for H. pylori indications
What is the practical generic entry path for PREVPAC?
In mature fixed-dose regimens, generic entry can occur via:
- ANDA for combination products matching approved labeling and dosing
- Component substitution under clinical practice patterns even absent a single-product ANDA
Even where a fixed-dose combination faces IP barriers, clinicians can often recreate regimens with generics, shrinking the remaining branded protection.
What patents protect PREVPAC and how strong is the remaining patent estate?
Featured snippet: Patent strength analysis requires the currently listed Orange Book patents for PREVPAC, including their expiration dates and claims scope. A complete patent estate summary cannot be produced here without that patent-by-patent dataset.
What patent types typically matter for PREVPAC-style triple regimens?
The most relevant claim categories, when present, are:
- Fixed-dose or co-pack configuration claims
- Formulation patents for granule, tablet, or dissolution characteristics of the PPI component within the regimen
- Method-of-use claims tied to eradication regimens
- Manufacturing method claims that can block supply even if the composition is generically available
How does patent scope translate into generic risk?
- Broad formulation claims can delay ANDA approvals if the generic cannot design around
- Narrow co-pack or method claims can be designed around or avoided through labeling and manufacturing changes
- If patents are largely expired or weakly enforceable, market dynamics turn into pricing competition among available generics
What is the Orange Book status of PREVPAC (lansoprazole clarithromycin amoxicillin) and which listings drive Paragraph IV risk?
Featured snippet: Orange Book status and any Paragraph IV litigation posture cannot be determined without the current Orange Book record for PREVPAC and associated patent listing history.
What to look for in the PREVPAC Orange Book record
A complete decision-grade Orange Book review would identify:
- Product listing(s) and strengths
- Each listed patent number
- Patent expiration dates and regulatory exclusivity end dates
- Applicant types: NDA holder vs ANDA filers and approval history
- Any “skinny label” or managed change patterns
How Paragraph IV challenges typically play out for legacy regimens
For older fixed-dose antibiotics and PPIs:
- Challenges often target formulation or combination-use patents if any remain listed
- If the combination regimen is not meaningfully patent-protected, ANDA approvals may proceed without complex litigation
- Competitive impact is more rapid when combination fixed-dose products are successfully launched, not when only individual components are available
Which companies sell PREVPAC competitors and how does PREVPAC compare with alternative H. pylori regimens?
Featured snippet: PREVPAC competes with other PPI-based triple regimens, bismuth quadruple approaches, and newer guideline-supported eradication strategies that may reduce clarithromycin susceptibility dependence.
Competitive set categories
- Clarithromycin-based triples (PPI + clarithromycin + antibiotic)
- Metronidazole-containing quadruples
- Bismuth quadruple regimens
- Susceptibility-guided or resistance-adapted regimens
What matters for head-to-head market uptake
- Eradication rate under local resistance distributions
- Tolerability and adherence in real-world use
- Payer formulary placement and prior authorization requirements
- Drug-drug interactions relative to comorbid populations
How does PREVPAC position under guideline shifts?
Clarithromycin-based triples have faced increasing scrutiny in many geographies due to resistance. That shifts net demand toward alternatives or test-and-treat pathways, which limits branded growth even where generic component substitution exists.
What generic entry risks exist for PREVPAC and what would a launch scenario look like?
Featured snippet: Generic entry risk depends on whether any enforceable Orange Book-listed patents remain for the fixed-dose PREVPAC regimen and whether ANDA filers can design around. Without the Orange Book record, a specific launch probability or timing cannot be calculated.
Scenario mapping for decision-grade planning
A typical planning grid uses:
- Patent clearance date(s)
- Expected ANDA approval timeline once patents are cleared
- Commercial ramp time
- PBM switching and contracting lead time
- Market share cannibalization from branded fixed-dose to combination generics and/or component recreation
What would be the main drivers of post-entry price compression?
- Presence of multiple ANDA entrants
- Number of interchangeable regimen options on formulary
- Ingredient cost trends for PPIs and antibiotics
- Volume commitments in wholesaler and hospital systems
What FDA regulatory milestones apply to PREVPAC and what is its current status?
Featured snippet: PREVPAC is an established FDA-approved regimen for H. pylori eradication; current “regulatory status” details require a current dataset from FDA labeling or Orange Book.
What regulatory events would materially affect commercial planning
- Supplement approvals altering formulation, packaging, or labeling
- REMS requirements (unlikely for this regimen)
- Ongoing manufacturing site changes affecting supply continuity
- Any safety label updates tied to antibiotic resistance concerns or adverse events
Key Takeaways
- PREVPAC is a mature, legacy H. pylori eradication combination where clinical development intensity has shifted to newer or alternative regimens.
- Commercial dynamics are dominated by generic component substitution, payer formularies, and clarithromycin resistance environment, which constrains branded growth.
- Decision-grade exclusivity, patent strength, and Paragraph IV risk cannot be fully quantified here without Orange Book and patent-listing event data.
- Market projection should be treated as a mature product case: stable-to-declining branded revenue with ongoing pressure from generics and regimen switching.
FAQs
- What is PREVPAC approved for and what is the standard dosing course length?
- How do clarithromycin resistance rates affect eradication outcomes for PREVPAC-like triple therapies?
- Can prescribers substitute generic lansoprazole/clarithromycin/amoxicillin for PREVPAC without losing efficacy?
- What types of patents could still block a generic fixed-dose PREVPAC product?
- Which alternative H. pylori regimens are most likely to displace clarithromycin-based triples in formularies?
References
- (No citable sources were provided in the prompt.)
